Second-line therapy for esophageal cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 6, 2007, Pages 871-876

  Martin, Mike G ^a   Govindan, Ramaswamy ^b   Morgensztern, Daniel ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Esophangeal cancer; Neoplasm; Refractory disease; Relapsed disease; Second line chemotherapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DEPSIPEPTIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; IRINOTECAN; LAPATINIB; NAVELBINE; NEDAPLATIN; PACLITAXEL; TEMOZOLOMIDE;

ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ESOPHAGUS CANCER; GENE TARGETING; HAND FOOT SYNDROME; HEALTH CARE AVAILABILITY; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PALLIATIVE THERAPY; REVIEW; SEPSIS;

ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; HUMANS; PALLIATIVE CARE; SALVAGE THERAPY;

EID: 34347238919     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.6.871     Document Type: Review

References (37)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83(1), 18-29 (1999).
3. Ajani J, Bekaii-Saab T, D'Amico TA et al. Esophageal Cancer Clinical Practice Guidelines. J. Natl Compr. Canc. Netw. 4(4), 328-347 (2006).
4. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol. 17(1), 2-9 (2007).
5. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83(10), 2049-2053 (1998).
6. Enzinger PC, Mayer RJ. Esophageal cancer. N. Engl. J. Med. 349(23), 2241-2252 (2003).
7. Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 4(2), 123-132 (1993).
8. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann. Surg. 234(3), 360-367 (2001).
9. Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann. Surg. 232(3), 353-361 (2000).
10. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J. Surg. Oncol. 90(3), 139-146 (2005).
11. Spiridonidis CH, Laufman LR, Jones JJ, Gray DJ, Cho CC, Young DC. A Phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer 78(10), 2070-2077 (1996).
12. Petrasch S, Welt A, Reinacher A, Graeven U, Konig M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br. J. Cancer 78 (4), 511-514 (1998).
13. Ilson DH, Saltz L, Enzinger P et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. 17(10), 3270-3275 (1999).
14. Bleiberg H, Conroy T, Paillot B et al. Randomised Phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur. J. Cancer 33(8), 1216-1220 (1997).
15. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15(1), 261-267 (1997).
16. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 20(8), 1996-2004 (2002).
17. Tebbutt NC, Norman A, Cunningham D et al. A multicentre, randomised Phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann. Oncol. 13(10), 1568-1575 (2002).
18. Murad AM, Santigo FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72(1), 37-41 (1993).
19. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 8(2), 163-168 (1997).
20. Nicolaou N, Conlan AA. Cyclophosphamide, doxorubicin and celestin intubation for inoperable oesophageal carcinoma. S. Afr. Med. J. 61(12), 428-431 (1982).
21. Levard H, Pouliquen X, Hay JM et al. 5-fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur. J. Surg. 164(11), 849-857 (1998).
22. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin. Oncol. 26(Suppl. 15), 12-20 (1999).
23. Fenchel K, Karthaus M, Steffens C et al. Taxanes. An effective 2nd line treatment of advanced esophageal cancer: a randomised trial. Proc. Am. Soc. Clin. Oncol. (1999) (Abstract 1088).
24. Metges J-D, Hennequin C, Ychou M et al. Docetaxel (DOC) as a second line chemotherapy in metastatic esophageal cancer (MEC): a French Study. Proc. Am. Soc. Clin. Oncol. 20 (2001) (Abstract 635).
25. Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest. New Drugs 20(1), 95-99 (2002).
26. Anderson SE, O'Reilly EM, Kelsen DE Ilson DH. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest. 21(4), 512-516 (2003).
27. Muro K, Hamaguchi T, Ohtsu A et al. A Phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann. Oncol. 15, 955-959 (2004).
28. Conroy T, Etienne PL, Adenis A et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J. Clin. Oncol. 14(1), 164-170 (1996).
29. Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer final results of a Phase II trial. Br. J. Cancer 92(12), 2129-2133 (2005).
30. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efftcacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res. 4(4), 1013-1019 (1998).
31. Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis. Esophagus 19(6), 473-476 (2006).
32. Mafune K, Yamada K, Imamura K, Kubota M, Kaminishi M. Docetaxel, 5-fluorouracil and nedaplatin as second-line chemotherapy for patients with esophageal cancer after esophagectomy: a pilot study. Proc. Am. Soc. Clin. Oncol. (2006) (Abstract 4140).
33. Lordick F, Von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory esophageal cancer. Br. J. Cancer 89(4), 630-633 (2003).
34. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al. Predictive factors for outcome in a Phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J. Clin. Oncol. 24(10), 1612-1619 (2006).
35. Adelstein DJ, Rybicki LA, Carroll MA, Rice TW, Mekhail T. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. Proc. Am. Soc. Clin. Oncol. 23 (2005) (Abstract 4054).
36. Tew WP, Shah M, Schwartz G, Kelsen D, Ilson DH. Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Presented at: Gastrointestinal Cancers Symposium Hollywood, Florida, 27-29 January 2005 (Abstract 49A).
37. Shah MA, Ramanathan RK, Ilson DH et al Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 24(33), 5201-5206 (2006).